TY  - JOUR
A1  - Schlegel, Patrick
A1  - Lang, Peter
A1  - Zugmaier, Gerhard
A1  - Ebinger, Martin
A1  - Kreyenberg, Hermann
A1  - Witte, Kai-Erik
A1  - Feucht, Judith
A1  - Pfeiffer, Matthias
A1  - Teltschik, Heiko-Manuel
A1  - Kyzirakos, Christina
A1  - Feuchtinger, Tobias
A1  - Handgretinger, Rupert
T1  - Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab
T2  - Haematologica
N2  - We report on posttransplant relapsed pediatric patients with B-precursor acute lymphoblastic leukemia with no further standard of care therapy who were treated with the T-cell engaging CD19/CD3-bispecific single-chain antibody construct blinatumomab on a compassionate use basis. Blast load was assessed prior to, during and after blinatumomab cycle using flow cytometry to detect minimal residual disease, quantitative polymerase chain reaction for rearrangements of the immunoglobulin or T-cell receptor genes, and bcr/abl mutation detection in one patient with Philadelphia chromosome-positive acute lymphoblastic leukemia. Blinatumomab was administered as a 4-week continuous intravenous infusion at a dosage of 5 or 15 μg/m2/day. Nine patients received a total of 18 cycles. Four patients achieved complete remission after the first cycle of treatment; 2 patients showed a complete remission from the second cycle after previous reduction of blast load by chemotherapy. Three patients did not respond, of whom one patient proceeded to a second cycle without additional chemotherapy and again did not respond. Four patients were successfully retransplanted in molecular remission from haploidentical donors. After a median follow up of 398 days, the probability of hematologic event-free survival is 30%. Major toxicities were grade 3 seizures in one patient and grade 3 cytokine release syndrome in 2 patients. Blinatumomab can induce molecular remission in pediatric patients with posttransplant relapsed B-precursor acute lymphoblastic leukemia and facilitate subsequent allogeneic hematopoietic stem cell transplantation from haploidentical donor with subsequent long-term leukemia-free survival.
Y1  - 2014
UR  - http://publikationen.ub.uni-frankfurt.de/frontdoor/index/index/docId/53436
UR  - https://nbn-resolving.org/urn:nbn:de:hebis:30:3-534367
SN  - 1592-8721
SN  - 0390-6078
N1  - Copyright© Ferrata Storti Foundation
VL  - 99
IS  - 7
SP  - 1212
EP  - 1219
PB  - Ferrata Storti Foundation
CY  - Pavia
ER  -